Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | MMP9 | P14780 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2842685 | 0.81 | RAB9A (0.52) | MMP1MMP13ALDH1A1KDM4EPOLB | |
| SCHEMBL16377465 | 0.77 | MMP1 (0.49) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL2840960 | 0.75 | MMP1 (0.44) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL3597949 | 0.74 | MMP1 (0.53) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL1244889 | 0.74 | MMP1 (0.53) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| Hydrochloric Acid SCHEMBL23120712 | 0.73 | MMP1 (0.51) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL2839000 | 0.72 | MMP1 (0.54) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL457576 | 0.72 | MMP2 (0.54) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL2142883 | 0.71 | MMP1 (0.50) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL13614850 | 0.71 | MMP1 (0.53) | MMP1MMP2MMP9MMP13L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4537315-B2 | — | — | 2010-09-01 | — | — | JP | claimed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | claimed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | claimed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| JP-2006510736-A | — | — | 2006-03-30 | — | — | JP | claimed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | claimed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | claimed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | claimed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1746888-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005112640-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | MMP1 4219/4885MMP2 3453/4885MMP9 3565/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | MMP1 4219/4885MMP2 3453/4885MMP9 3565/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | MMP1 4219/4885MMP2 3453/4885MMP9 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.